Lansoprazole
Product Images NDC 54868-6197

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 54868-6197). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lansoprazole Delayed-release Capsules Usp 30 mg Label (30mg Package Label)

A white rectangular pharmaceutical label for Lansoprazole delayed-release 30 mg tablets. It displays the labeler as Physicians Total Care, Inc., Tulsa, OK, and includes a lot number and expiration date. The manufacturing location noted is Jerusalem, Israel. A barcode with a numeric code is also present at the bottom of the label.*

FDA Label Image

Lansoprazole Delayed-release Capsules Usp 15 mg Label (6197)

Packaging label for Lansoprazole DR 15 mg distributed by Physicians Total Care, Inc. The label includes NDC 54868-6197-0, a lot number placeholder, an expiration date marked 01/60, and manufacturer information indicating Teva Pharmaceuticals, Jerusalem, Israel. A barcode and numeric code are also present on the label.*

FDA Label Image

Chemical Structure (66af6a5f 0ec4 4d58 8abb 583d1b16549d 01)

Chemical structure diagram of lansoprazole, showing its molecular framework including a benzimidazole ring, sulfoxide group, and substituted pyridine ring.*

FDA Label Image

Figure 1 (66af6a5f 0ec4 4d58 8abb 583d1b16549d 02)

Line graph showing the mean severity of daytime heartburn over days from start of treatment. The graph compares placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD groups, illustrating changes in heartburn severity across a 60-day period.*

FDA Label Image

Figure 2 (66af6a5f 0ec4 4d58 8abb 583d1b16549d 03)

A line graph showing the mean severity of night heartburn over days from the start of treatment. It compares three groups: placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD, with severity decreasing over time for the Lansoprazole groups more than the placebo group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.